Tag: TCT 2018
ADVERTORIAL: “We are now at a new era of TAVI where we have very high rates of device success”
CAUTION: The ACURATE neo aortic valve system is CE marked. In the USA, it is an investigational ...
Orsiro may be the new benchmark for comparison in drug-eluting stent trials
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 September, San Diego,...
The resurgence of renal denervation
More than ever before, arterial hypertension represents one of the greatest health threats and c...
Pulmonary artery denervation: A novel approach to managing pulmonary hypertension
According to the results of PADN-5, pulmonary artery denervation (PADN) is associated with signi...
TCT 2018: Multivessel NIRS is feasible, safe and can predict future events
Ron Waksman
The Lipid Rich Plaque (LRP) study indicates that cardiac patients with a high li...
TCT 2018: Sham-controlled trial indicates indirect annuloplasty reduces mitral regurgitation
REDUCE-FMR indicates that indirect annuloplasty with the Carillon device (Cardiac Dimensions) is...
TCT 2018: Durable tricuspid regurgitation reduction with MitraClip
Data from the TriValve Registry—an international multicentre, retrospective, multidevice, regist...
TCT 2018: Severe prosthesis-patient mismatch linked to increased mortality at one year
The largest study to date of prosthesis-patient mismatch following transcatheter aortic valve im...
TCT 2018: IVUS-guided PCI reduces target vessel failure in all-comers population
Jun-jie Zhang (Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nan...
TCT 2018: Orsiro continues to have lower rates of target lesion failure than Xience
Two-year data from the BIOFLOW-V randomised trial—which compared a sirolimus stent with a biodeg...
TCT 2018: One-year real-world results show Portico TAVI system reduces severe aortic stenosis
According to one-year results from the PORTICO I study, which were presented during a late-breaking ...
TCT 2018: Longest-term data to date for CoreValve study show excellent valve durability out to five years
New data presented at 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 Septem...
TCT 2018: Use of Impella in cardiogenic shock patients associated with relative 24% increase in survival
A new analysis of data from the Impella (Abiomed) Quality (IQ) Database shows a relative increas...
TCT 2018: LEADERS FREE II confirm favourable results for BioFreedom
The primary endpoint results of the LEADERS FREE II trial were presented at the 2018 Transcathet...
TCT 2018: Restore drug-coated balloon matches Resolute for small vessel lesions
Data presented at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 Septem...
TCT 2018: FFRangio may provide a faster and easier approach to physiological assessment
The FAST-FFR trial, which was presented at the 2018 Transcatheter Cardiovascular Therapeutics (T...
TCT 2018: Audience claps as COAPT shows MitraClip reduces HF hospitalisations
Delegates at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21-25 September, ...
TCT 2018: Lower rate of stent thrombosis with Resolute Onyx vs. Orsiro
Data presented yesterday at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21...
TCT 2018: Infraredx to present results of the LRP study
Results from the highly anticipated LRP (Lipid-Rich Plaque) study will be presented during a lat...
TCT 2018: Corindus to feature the CorPath GRX system at conference
Corindus Vascular Robotics is to feature its CorPath GRX system at the 2018 Transcatheter Cardio...
Twenty thousand patients have now been treated with RenalGuard therapy
RenalGuard Solutions has announced the treatment of 20,000 patients with RenalGuard for the prev...
Juan F Granada
Juan F Granada (president and CEO, Cardiovascular Research Foundation, New York, USA) wanted to ...
